Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients
Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients
This study will evaluate the efficacy and safety of vildagliptin 50 mg bid in elderly
 patients with Type 2 Diabetes Mellitus (T2DM).
Inclusion Criteria:

 -  age: ≥ 70 years inclusive at Visit 1.

 -  patients with a confirmed diagnosis of T2DM

 -  HbA1c of ≥ 7% and ≤10.0% by central laboratory at Visit 1 and assessed by the
 investigator to be inadequately controlled

 -  body mass index (BMI) in the range of 19-45kg/m2

 Exclusion Criteria:

 -  FPG ≥ 270 mg/dL (≥ 15.0 mmol/L)

 -  previous or current participation in any vildagliptin clinical study.

 -  history of hypersensitivity to DPP-4 inhibitors.

 -  concurrent medical condition that may interfere with the interpretation of efficacy
 and safety data during the study.

 -  donation of blood or significant blood loss equaling to at least one unit of blood
 within the past 2 weeks of start of study or a blood transfusion within the past 12
 weeks or planned regular transfusions during the study period Other protocol-defined
 inclusion/exclusion criteria may apply